- Home
- OCX
as 07-26-2024 4:00pm EST
OncoCyte Corp focuses on the discovery, development, and commercialization of novel, non-invasive, liquid biopsy diagnostics for the early detection of cancer. The company develops diagnostic tests based on liquid biopsies using blood or urine samples for detecting lung, bladder, and breast cancers. In addition, it also develops screening diagnostics as potential replacements for screening imaging procedures that do not meet the needs of patients, health care providers or payers.
| Founded: | 2009 | Country: | United States |
| Employees: | N/A | City: | IRVINE |
| Market Cap: | 40.4M | IPO Year: | N/A |
| Target Price: | $4.06 | AVG Volume (30 days): | 64.3K |
| Analyst Decision: | Buy | Number of Analysts: | 4 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -5.08 | EPS Growth: | N/A |
| 52 Week Low/High: | $2.08 - $4.34 | Next Earning Date: | 08-08-2024 |
| Revenue: | $1,382,000 | Revenue Growth: | 57.94% |
| Revenue Growth (this year): | 1.26% | Revenue Growth (next year): | 161.63% |
Stock Insider Trading Activity of Oncocyte Corporation (OCX)
| Name | Ticker | Relationship | Date | Transaction | Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| Arno Andrew | OCX | Director | Apr 11 '24 | Buy | $2.95 | 33,898 | $99,999.10 | 69,054 | SEC Form 4 |
| Riggs Josh | OCX | CEO and President | Apr 11 '24 | Buy | $2.95 | 3,390 | $10,000.50 | 3,505 | SEC Form 4 |
| BROADWOOD PARTNERS, L.P. | OCX | 10% Owner | Apr 11 '24 | Buy | $2.92 | 2,420,000 | $7,057,688.00 | 4,929,066 | SEC Form 4 |
| BROADWOOD PARTNERS, L.P. | OCX | 10% Owner | Apr 11 '24 | Buy | $0.00 | 0 | $0.00 | 4,929,066 | SEC Form 4 |
Latest Oncocyte Corporation News
OCX Breaking Stock News: Dive into OCX Ticker-Specific Updates for Smart Investing
GlobeNewswire
16 days ago
MedTech Gurus Podcast Features Oncocyte CEO Josh Riggs in "Take Advantage of the Moment" Episode
GlobeNewswire
a month ago
Oncocyte Bolsters Executive Team with Key CFO Appointment: PRISM MarketView Highlights Strategic Leadership Move
GlobeNewswire
a month ago
Oncocyte Appoints Andrea James as Chief Financial Officer
ACCESSWIRE
2 months ago
OncoCyte's Innovative Approach: Potential in Precision Diagnostics
GlobeNewswire
2 months ago
Breakthrough in Kidney Transplant Monitoring: PRISM MarketView Spotlights Oncocyte's VitaGraft Study
GlobeNewswire
2 months ago
Favorable Oncocyte VitaGraft Kidney Study Results Published in the New England Journal of Medicine
GlobeNewswire
2 months ago
Oncocyte Reports First Quarter 2024 Financial Results
GlobeNewswire
2 months ago
Oncocyte to Announce First Quarter 2024 Financial Results
Compare OCX vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "OCX Oncocyte Corporation - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.